Other OTC - Delayed Quote USD

Genfit S.A. (GNFTF)

2.9500 0.0000 (0.00%)
At close: April 15 at 12:25 PM EDT
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
28,565.0000
28,565.0000
20,195.0000
80,069.0000
765.0000
Cost of Revenue
341.0000
341.0000
251.0000
162.0000
202.0000
Gross Profit
28,224.0000
28,224.0000
19,944.0000
79,907.0000
563.0000
Operating Expense
55,389.0000
55,389.0000
47,259.0000
47,536.0000
78,072.0000
Operating Income
-27,165.0000
-27,165.0000
-27,315.0000
32,371.0000
-77,509.0000
Net Non Operating Interest Income Expense
-1,419.0000
-1,419.0000
-3,676.0000
30,944.0000
-10,227.0000
Other Income Expense
72.0000
72.0000
7,157.0000
6,157.0000
-13,913.0000
Pretax Income
-28,514.0000
-28,514.0000
-23,836.0000
69,474.0000
-101,649.0000
Tax Provision
380.0000
380.0000
-116.0000
2,215.0000
-428.0000
Net Income Common Stockholders
-28,894.0000
-28,894.0000
-23,719.0000
67,259.0000
-101,221.0000
Diluted NI Available to Com Stockholders
-28,894.0000
-28,894.0000
-23,719.0000
67,259.0000
-101,221.0000
Basic EPS
-0.58
--
-0.48
1.51
-2.60
Diluted EPS
-0.58
--
-0.48
1.23
-2.60
Basic Average Shares
49,700.2230
--
49,673.9360
44,739.7560
38,858.6170
Diluted Average Shares
49,700.2230
--
49,673.9360
55,613.6340
38,858.6170
Total Operating Income as Reported
-26,580.0000
-26,580.0000
-27,289.0000
31,816.0000
-82,897.0000
Total Expenses
55,730.0000
55,730.0000
47,510.0000
47,698.0000
78,274.0000
Net Income from Continuing & Discontinued Operation
-28,894.0000
-28,894.0000
-23,719.0000
67,259.0000
-101,221.0000
Normalized Income
-28,965.0424
-28,965.0424
-30,841.1698
61,298.3001
-87,366.4346
Interest Income
1,709.0000
1,709.0000
137.0000
274.0000
1,442.0000
Interest Expense
4,624.0000
4,624.0000
4,410.0000
4,955.0000
11,777.0000
Net Interest Income
-1,419.0000
-1,419.0000
-3,676.0000
30,944.0000
-10,227.0000
EBIT
-23,890.0000
-23,890.0000
-19,426.0000
74,429.0000
-89,872.0000
EBITDA
-22,236.0000
-22,236.0000
-17,594.0000
77,171.0000
-86,313.0000
Reconciled Cost of Revenue
341.0000
341.0000
251.0000
162.0000
202.0000
Reconciled Depreciation
1,654.0000
1,654.0000
1,832.0000
2,742.0000
3,559.0000
Net Income from Continuing Operation Net Minority Interest
-28,894.0000
-28,894.0000
-23,719.0000
67,259.0000
-101,221.0000
Total Unusual Items Excluding Goodwill
72.0000
72.0000
7,157.0000
6,157.0000
-13,913.0000
Total Unusual Items
72.0000
72.0000
7,157.0000
6,157.0000
-13,913.0000
Normalized EBITDA
-22,308.0000
-22,308.0000
-24,751.0000
71,014.0000
-72,400.0000
Tax Rate for Calcs
0.0000
0.0000
0.0000
0.0000
0.0000
Tax Effect of Unusual Items
0.9576
0.9576
34.8302
196.3001
-58.4346
12/31/2020 - 1/27/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

GLSHQ Gelesis Holdings, Inc.
0.0198
0.00%
 
LOBEF Lobe Sciences Ltd.
0.0144
-5.59%
 
CLGN CollPlant Biotechnologies Ltd.
5.26
+0.77%
 
SRZN Surrozen, Inc.
9.25
+0.43%
 
PHIO Phio Pharmaceuticals Corp.
0.8299
+32.57%
 
VCNX Vaccinex, Inc.
4.9400
+1.65%
 
GLMD Galmed Pharmaceuticals Ltd.
0.3641
-2.02%
 
NRSN NeuroSense Therapeutics Ltd.
1.3500
-4.93%
 
ENLV Enlivex Therapeutics Ltd.
1.2700
-3.79%
 
ADIL Adial Pharmaceuticals, Inc.
1.9000
-1.55%